Back to Journals » Biologics: Targets and Therapy » Volume 6
Review

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
15,072 | Dovepress* | 11,217+ | 2,522 | 13,739 | |
PubMed Central* | 3,855 | 1,180 | 5,035 | ||
Totals | 15,072 | 3,702 | 18,774 | ||
*Since 25 September 2012 +Since July 2016 |
View citations on PubMed Central and Google Scholar